Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The FDA

<< Previous

Bullboard Posts

Next >>

Comment by O12009on Sep 06, 2022 6:44am

216 Views

Post# 34943286

RE:The FDA

Oilminerdeluxe wrote: Just a thought. Can the FDA say "Ok this looks interesting, but first give us 12 new patients that were not treated the wrong way. Then we can discuss the BTD." ??

Hopefully the ones that were treated the right way will be enough for them, but I figured I could ask the question anyway.

They did give them 12 patients treated the right way. 13~ 25. The FDA has issued the Fasrtrack designation and that gave us closer and more frequent contact with them and as stated by SF , it seems the Breakthrough designation will be received after Dec 2022 and commercial approval early 2023.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments